Novel 1,2,3 Triazole Antifungal Agents and Preparation Thereof

ABSTRACT

The present application relates to 1,4-disubstituted 1,2,3-Triazole antifungal agents of the formula (I) wherein, R1 is halogens such as fluorine, chlorine or bromine, CF3, alkyl; R2 is alkyl or hydrogen; R3 is halogen selected from fluorine, chlorine or bromine; and n is 0 or 1. The application further relates to the synthesis of said compounds, to fungicidal compositions containing said compounds and to their use in a method for treating fungal infections.

FIELD OF THE INVENTION

The present invention relates to novel triazole antifungal agents of the formula (I).

Wherein, R₁ is halogens such as fluorine, chlorine or bromine, CF₃, alkyl;

-   R₂ is alkyl or hydrogen; -   R₃ is halogen selected from fluorine, chlorine or bromine; and n is     0 or 1.

The present invention also relates to a process for the preparation of the novel antifungal agents of the formula (I) from alkynols and 2-azidophenols.

BACKGROUND AND PRIOR ART

Triazole moiety is an important and frequent insecticide, agrochemical structure feature of many biological active compound as cytocrome p450 enzyme inhibitors and peptide analog inhibitor. The azole class of antifungal agent is chemical either an imidazole or a triazole group joined to an asymmetric carbon atom as their functional pharmacophore treatment for these infection azole like antifungal agent are Ketoconazole, Fluconazole, Voriconazole and Itraconazole 1, 2, 4-triazole are as analgesic antiasthmatic, antibacterial, anticholinergic activity. They are aromatic ring compounds similar to the azole, pyrazole and imidazole but with an additional nitrogen atom in the ring structure. Like the azoles, triazoles are used in many antifungal drugs and fungicides, but the triazole-based drugs are more selective for fungi than mammalian cells than the azole-based antifungal compounds.

In recent years, triazole-containing compounds have become potential targets for drug discovery. 1,2,3-triazole moiety is an important pharmacophore present in diverse medicinally important molecules with potential applications as anticancer, HIV protease inhibitors, anti-tubercular, antibacterials, and as a core structure of azole class of antifungal drugs (Agalave et al., 2011). There were very few antifungal agents (mainly polyenes) in clinical use till 1980. The development of azoles namely; ketoconazole, miconazole, fluconazole in 80's and itraconazole, posaconazole, voriconazole in 90's resulted in rapid advancement of antifungal therapy. These azoles were effective against fungal pathogens that were refractory to the polyenes and available both in intravenous and oral formulations. However over the years, many fungal pathogens developed resistance against fluconazole and other azoles due to their wide use as first line drugs in treatment. Triazole analogues of several bioactive compounds have recently been reported. Examples are those of the well-known highly functionalizcd antiviral cyclic amino acid derivatives oscltamivir and zanamivir. The 1,2,3-triazole moiety is a constituent part of many modified nucleosides or carbanucleosides with antiviral, anti-HIV or cytostatic activities. However, the scope of triazole chemistry is not confined to drug discovery.

Article titled “Regio-selective synthesis of 1,4-disubstituted-1,2,3-triazoles and evaluation of their antimicrobial activity” by R Parveen et al. published in Asian Journal of Biomedical and Pharmaceutical Sciences, 15 Jun. 2014, 4(32), 44-47 reports a series of 1,4-disubstituted 1,2,3-triazoles synthesized via Cu(I) catalyzed reaction between terminal alkyne and substituted phenyl azides. The synthesized triazoles are characterized by 1 H NMR and mass spectral techniques. The synthesized compounds are evaluated for their antimicrobial activity against Escherichia coli, Staphylococcus aureus, Aspergillus niger by well diffusion method.

Article titled “Regioselective syntheses of fully-substituted 1,2,3-triazoles: the CuAAC/C-H bond functionalization nexus” by L Ackermann et al. published in Org. Biomol. Chem., 2010,8, 4503-4513 reports regioselective synthesis of 1,4,5-trisubstituted 1,2,3-triazoles by three different strategics, relying on (i) the interception of stoichiometrically formed 5-cuprated- 1,2,3-triazoles, (ii) the use of stoichiometrically functionalized alkynes or (iii) catalytic C═H bond functionalizations.

Article titled “Efficient continuous-flow synthesis of novel 1,2,3-triazole-substituted β-aminocyclohexanecarboxylic acid derivatives with gram-scale production” by S B Otvös et al. published in Beilstein J Org Chem, 2013, 9, pp 1508-16 reports preparation of novel multi-substituted 1,2,3-triazole-modified β-aminocyclohexanecarboxylic acid derivatives in a simple and efficient continuous-flow procedure. The 1,3-dipolar cycloaddition reactions are performed with copper powder as a readily accessible Cu(I) source. Initially, high reaction rates was achieved under high-pressure/high-temperature conditions. Subsequently, the reaction temperature was lowered to room temperature by the joint use of both basic and acidic additives to improve the safety of the synthesis, as azides were to be handled as unstable reactants.

Most useful and powerful procedure for the synthesis of 1,2,3-triazolcs is the Huisgen 1,3-dipolar cycloaddition of organic azides with acetylenes. The classical Huisgen reaction, thermally induced, gives an approximate 1:1 mixture of 1,4- and 1,5-disubstituted 1,2,3-triazole isomers. However, when Cu(I) catalysis is applied, the reaction becomes regioselective, exclusively yielding the 1,4-regioisomer within a relatively short reaction time. Recently, Cu(I)-catalyzed azide-alkyne cycloaddition (CuAAC) has become the basis of the so-called click chemistry concept due to its wide applicability and efficiency.

Moreover, other drawbacks associated with azoles, such as narrow spectrum, low oral bioavailability, drug-drug interactions, and hepatic toxicity reduced their efficacy and needs to be overcome.

Therefore, there is need for development of new azole derivatives with broad spectrum activity and better efficacy and safety. Accordingly the inventors have designed three classes of 1,2,3 -triazole compounds as novel anti-fungal agents. These compounds are easy to synthesize from simple starting materials, processes are green, convergent, carried at room temperature and highly scalable.

OBJECTIVE OF INVENTION

The main objective of the present invention is to provide a novel triazole antifungal agents of formula (I).

Another objective of the present invention is to provide a process for the synthesis of novel triazole antifungal agents of formula (I).

SUMMARY OF THE INVENTION Accordingly, the present invention provides a novel triazole antifungal agents of formula (I).

Wherein, R₁ is halogens such as fluorine, chlorine or bromine, CF₃, alkyl;

-   R₂ is alkyl or hydrogen; -   R₃ is halogen selected from fluorine, chlorine or bromine; -   and n is 0 or 1.

In an aspect, the present invention provides a process for the synthesis of novel triazole antifungal agents of formula (I) from alkynols and 2-azidophenols.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 depicts Absorbance spectrum.

FIG. 2 depict ROS production in C. albicans ATCC 24433.

DETAILED DESCRIPTION OF THE INVENTION

The invention will now be described in detail in connection with certain preferred and optional embodiments, so that various aspects thereof may be more fully understood and appreciated.

The present invention provides a novel triazole antifungal agents of formula (I) and process for preparation thereof.

In an embodiment, the present invention provides a novel antifungal agents compound of formula (I) (1/Type-I or 2/Type-II),

Wherein, R₁ is halogens such as fluorine, chlorine, bromine, CF₃, alkyl;

-   R₂ is alkyl or hydrogen; -   R₃ is halogen selected from fluorine, chlorine or bromine; -   and n is 0 or 1.

In another preferred embodiment, the compounds of formula (I) are:

-   -   i.         4-Chloro-2-(4-((3,5-dimethylphenyl)(hydroxy)methyl)-1H-1,2,3-triazol-1-yl)phenol         (1aa).     -   ii.         2-(4-((3,5-Bis(trifluoromcthyl)phenyl)(hydroxy)methyl)-1H-1,2,3-triazol-1-yl)-4-chlorophenol(1ba),     -   iii.         4-Chloro-2-(4-(1-hydroxy-1-phenylpropyl)-1H-1,2,3-triazol-1-yl)phenol(,     -   iv. 5-Chloro-2-(4-((3,5-dimethylphenyl)(hydroxy)methyl)-1         H-1,2,3-triazol-1-yl)phenol(1ab),     -   v.         5-Chloro-2-(4-(1-hydroxy-1-phenylethyl)-1H-1,2,3-triazol-1-yl)phenol(2cb),     -   vi.         4-Chloro-2-(4-(2-hydroxy-2-phenylethyl)-1H-1,2,3-triazol-1-yl)phenol(1ea),     -   vii.         5-Chloro-2-(4-(2-hydroxy-2-phenylethyl)-1H-1,2,3-triazol-1-yl)phenol(1eb),     -   viii.         4-Chloro-2-(4-(2-hydroxy-2-phenylpropyl)-1H-1,2,3-triazol-1-yl)phenol(2fa),     -   ix.         5-Chloro-2-(4-(2-hydroxy-2-phenylpropyl)-1H-1,2,3-triazol-1-yl)phenol(2fb),     -   x.         4-Chloro-2-(4-(2-hydroxy-2-phenylbutyl)-1H-1,2,3-triazol-1-yl)phenol(2ga),     -   xi.         5-Chloro-2-(4-(2-hydroxy-2-phenylbutyl)-1H-1,2,3-triazol-1-yl)phenol(2gb),     -   xii.         4-chloro-2-(4-(2-hydroxy-2-phenylhexyl)-1H-1,2,3-triazol-1-yl)phenol(2ha),     -   xiii.         4-Chloro-2-(4-(2-hydroxy-2,2-diphenylethyl)-1H-1,2,3-triazol-1-yl)phenol(2ia),     -   xiv.         5-Chloro-2-(4-(2-hydroxy-2,2-diphenylethyl)-1H-1,2,3-triazol-1-yl)phenol(2ib),     -   xv.         2-(4-(2-(3,5-Bis(trinuoromethyl)phenyl)-2-hydroxyethyl)-1H-1,2,3-triazol-1-yl)-4-chlorophenol(1ja),     -   xvi.         2-(4-(2-(3,5-Bis(trifluoromethyl)phenyl)-2-hydroxyethyl)-1H-1,2,3-triazol-1-yl)-5-chlorophenol(1jb),     -   xvii.         2-(4-(2-(3,5-Bis(trifluoromethyl)phenyl)-2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)-4-chlorophenol(2sa),     -   xviii.         2-(4-(2-(3,5-Bis(trifluoromethyl)phenyl)-2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)-5-chlorophenol(2sb),     -   xix.         4-Chloro-2-(4-(2-(2,4-difluorophenyl)-2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)phenol(2ka),     -   xx.         4-Chloro-2-(4-(2-(2,4-dichlorophenyl)-2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)phenol(2ma),     -   xxi.         4-Chloro-2-(4-(2-(4-(dimethylamino)phenyl)-2-hydroxycthyl)-1H-1,2,3-triazol-1-yl)phenol         (2pa),     -   xxii.         5-Chloro-2-(4-(2-(2,4-difluorophenyl)-2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)phenol         (2kb),     -   xxiii.         5-Chloro-2-(4-(2-(2,4-dichlorophenyl)-2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)phenol         (2mb),     -   xxiv.         5-Chloro-2-(4-(2-(2-fluoro-4-(trifluoromethyl)phenyl)-2-hydroxyethyl)-1H-1,2,3-triazol-1-yl)phenol         (2ob),     -   xxv.         2-(4-(2-(2,4-Difluorophenyl)-2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)-5-fluorophenol         (2kc),     -   xxvi.         2-(4-(2-(2,4-Dichlorophenyl)-2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)-5-fluorophenol         (2mc),     -   xxvii.         5-Fluoro-2-(4-(2-(2-fluoro-4-(trifluoromethyl)phenyl)-2-hydroxyethyl)-1H-1,2,3-triazol-1-yl)phenol         (2oc),     -   xxviii.         5-Fluoro-2-(4-(2-(4-fluorophenyl)-2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)phenol         (2qc),     -   xxix.         2-(4-(2-(4-Chlorophenyl)-2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)-5-fluorophenol         (2lc),     -   xxx.         2-(4-(2-(4-Bromophenyl)-2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)-5-fluorophenol         (2nc),     -   xxxi.         4-Chloro-2-(4-(2-(4-fluorophenyl)-2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)phenol         (2qa),     -   xxxii.         4-Chloro-2-(4-(2-(4-chlorophenyl)-2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)phenol         (2la),     -   xxxiii.         2-(4-(2-(4-Bromophenyl)-2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)-4-chlorophenol         (2na),     -   xxxiv.         5-Chloro-2-(4-(2-(4-fluorophenyl)-2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)phenol         (2qb),     -   xxxv.         5-Chloro-2-(4-(2-(4-chlorophenyl)-2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)phenol         (2lb),     -   xxxvi.         2-(4-(2-(4-Bromophenyl)-2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)-5-chlorophenol         (2nb),     -   xxxvii.         2-(4-(2-(4-Fluorophenyl)-2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)phenol         (2qd),     -   xxxviii.         2-(4-(2-(4-Chlorophenyl)-2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)phenol         (2ld),     -   xxxix.         2-(4-(2-(4-Bromophenyl)-2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)phenol         (2nd)     -   xl.         2-(4-(2-(2,4-Difluorophenyl)-2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)phenol         (2kd)     -   xli.         2-(4-(2-(2,4-Dichlorophenyl)-2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)phenol         (2md).

In one embodiment, the present invention provides a process for the synthesis of novel triazole compounds of formula (I), with >75% yields comprising the steps of:

-   -   a. Adding sodium ascorbate and copper (II) sulfate to a solution         of 2-azidophenols 5 and alkyne 4 or 7 in ¹BuOH:H₂O and stirring         the resulting brick reddish mixture vigorously to obtain the         reaction mixture;     -   b. Work-up and purification of the completed reaction mixture of         step (a) to afford the desired product.

The above process is shown below in Scheme 1:

The 2-azidophenols is selected from the group of compounds consisting of formula 5y.

The alkyne is selected from the group of compounds consisting of formula 4x or 7x.

In another embodiment, the invention discloses use of compounds of Formula (I) as antifungal agents.

In another preferred embodiment, the invention discloses pharmaceutical preparations which comprise a compound of Formula (I) in association with at least one pharmaceutical excipient known in art. These excipients are added to the composition for a variety of purposes.

The pharmaceutical preparations can be selected from various dosage forms such as solid dosage form like tablets, capsules, pellets, powders, soft gelatin capsules, and the like and oral liquids. The tablets can be prepared as conventional dosage forms such as immediate release, sustained release, modified release or controlled release.

The pharmaceutical compositions can be prepared using conventional techniques well known in the art.

According to another embodiment, the invention provides method for treating or preventing antifungal infections in a subject, wherein said method comprises administering therapeutically effective amounts of the compounds of formula (I) of the present invention or pharmaceutical composition comprising the same. The compounds of the present invention can also be administered optionally with other actives depending on the disease conditions.

As used herein the term “therapeutically effective amount” means an amount used in the pharmaceutical preparations to achieve the desired therapeutic effect.

The amount/quantity of the compound used in pharmaceutical compositions of the present invention will vary depending upon the body weight of the patient and the mode of administration and can be of any effective amount to achieve the desired therapeutic effect.

The invention further provides use of the compounds of Formula (I) in the preparation of pharmaceutical medicament.

The antifungal activity of novel compounds of formula (I) (1Type-I or 2/Type-II) is summarized below in Table: 1 and Table: 2.

The following examples, which include preferred embodiments, will serve to illustrate the practice of this invention, it being understood that the particulars shown are by way of example and for purpose of illustrative discussion of preferred embodiments of the invention.

EXAMPLES Example 1 Experimental Procedure for Synthesis of Alkynols (4, 7) and 2-Azidophenols (5):

-   -   A. Mg (518 mg, 28.3 mmol) was flame dried in a two neck R. B.         flask fitted with a reflux condenser and cooled to room         temperature in argon atmosphere. Dry THF (30 mL) was introduced         followed by a few crystals of iodine. Half of the total volume         of n-BuCl (2.23 mL, 28.3 mmol) was added and the contents were         refluxed till the generation of Grignard reagent. Heating was         removed and rest of n-BuCl was added. Stirring was continued at         room temperature till all the magnesium was consumed. Then the         reaction mixture was cooled to 0° C. and acctylene gas was         bubbled into it over 15 min. benzaldehyde (1.0 g, 9.4 mmol) in         THF (20 mL) was added at 0° C. and stirred for 6 h. The reaction         was quenched with saturated NH₄Cl solution, diluted with water,         and extracted with ethyl acetate. The combined organic layers         were dried over Na₂SO₄, concentrated and purified on silica gel         (10% ethyl acctate in petroleum ether) to give 4 (1.08 g, 86%)         as a yellowish oil.

-   -   B. The amine 8 (1.0 eq.) was taken in 250 ml R. B. flask then         water was added and it followed by HCl (6 eq.). To this mixture         cold solution of NaNO₂ (1.0 eq.) was added at 0° C. and reaction         was allowed for stirring for 30 min. The reaction mixture was         became clear solution. The NaN₃ (1.0 eq.)was added slowly over         10 min and the reaction was allowed for stirring for 6 h at rt.         The reaction mixture was diluted and extracted with EtOAc. The         organic layer was dried over Na₂SO₄ and the solvents were         evaporated under reduced pressure. The product (5) was purified         by column chromatography.

-   -   C. Zn (5.0 eq). propargyl bromide (3.0 eq), in THF was stirred         vigorously for 30 min, to which a solution of ketone/aldehyde 6         (1.0 eq) in THF was added and the stirring was continued for         another 30 min. The reaction mixture was cooled to 0° C. and         saturated NH₄Cl was added drop wise for 30 min and stirring was         continued overnight. Reaction mixture was filtered through         Celite pad and the solvent was evaporated under vacuum and         extracted with ethyl acetate, washed with brine, dried (Na₂SO₄),         and concentrated. Purification of the crude by column         chromatography (10% ethyl acetate in petroleum ether) afforded 7         (64%) as colorless syrup.

Example 2 Experimental Procedure for Synthesis of Triazole (1/Type I):

To a solution of azide 5 (1.0 eq.) and alkyne 4 (1.1 eq.) in ¹BuOH:H₂O (3:1) at room temperature, sodium ascorbate (0.95 eq.) and CuSO₄ (0.2 eq.) were added and the resulting brick reddish mixture was stirred vigorously for 10 min. The reaction mixture was diluted and extracted with EtOAc. The organic layer was dried over Na₂SO₄ and the solvents were evaporated under reduced pressure. The product was purified by column chromatography.

Example 3 Experimental Procedure for Synthesis of Triazole (2/Type II):

To a solution of azide 5 (1.0 eq.) and alkyne 7 (1.1 eq.) in ^(t)BuOH: H₂O (3:1) at room temperature, sodium ascorbate (0.95 eq.) and CuSO₄ (0.2 eq.) were added and the resulting brick reddish mixture was stirred vigorously for 10 min. The reaction mixture was diluted and extracted with EtOAc. The organic layer was dried over Na₂SO₄ and the solvents were evaporated under reduced pressure. The product was purified by column chromatography.

Example 4

4-Chloro-2-(4-((3,5-dimethylphenyl)(hydroxy)methyl)-1H-1,2,3-triazol-1-yl)phenol (1aa):

Isolated by column chromatography (pet.ether/AcOEt=6:4, R_(ƒ)=0.3). The title compound was determined as colourless solid (86%). Mp: 191-193° C.; ¹H NMR (200 MHz, CDCl₃): δ2.34 (s, 6 H), 2.74 (d, J=3.5 Hz, 1H), 6.06 (d, J=2.9 Hz, 1 H), 7.00 (s, 1 H), 7.08-7.16 (m, 2 H), 7.26 (dd, J=2.3, 8.8 Hz, 2H), 7.37 (d, J=2.4 Hz, 1H), 7.88 (s, 1 H), 9.91 (s, 1H) ppm; ¹³C NMR (50 MHz, CDCl₃+MeOH (D₄)): δ21.3 (q, 2 C), 69.4 (d), 119.1 (d), 119.6 (d), 120.2 (d), 120.4 (d), 121.4 (s), 124.1 (d, 2 C), 130.1 (d), 135.0 (s), 138.5 (s, 2 C), 141.2 (s), 150.0 (s), 151.6 (s) ppm; IR(cm⁻¹): 3306, 3136, 2944, 1645, 1564, 1442, 1318, 1262, 1063, 875, 751, 669; HRMS(ESI) calcd for C₁₇H₁₇O₂N₃Cl(M⁺+H): 330.1004; found: 330.1004.

Example 5

2-(4-((3,5-Bis(trifluoromethyl)phenyl)(hydroxy)methyl)-1H-1,2,3-triazol-1-yl)-4-chlorophenol (1ba):

Isolated by column chromatography (pct.ether/AcOEt=6.4, R_(ƒ)=0.3). The title compound was determined as colourless solid (83%). Mp: 211-213° C.; ¹H NMR (200 MHz, CDCl₃+MeOH (D₄)): δ5.99 (s, 1H), 6.81 (d, J=8.7 Hz, 1H), 7.06 (dd, J=2.5, 8.7 Hz, 1H), 7.58 (d, J=2.5 Hz, 1H), 7.64 (bs, 1H), 7.86 (bs, 2H), 8.11 (s, 1H) ppm; ¹³C NMR (50 MHz, CDCl₃+MeOH (D₄)): δ67.1 (d), 117.9 (d), 120.3 (s), 120.5 (d, t, J=3.7 Hz), 123.1 (d), 123.5 (d, 2C), 124.2 (s), 124.6 (s), 125.7 (s), 126.4 (d, J=1.8 Hz), 129.1 (d), 130.6 (s, d, J=33.3 Hz), 131.9 (s, d, J=33.7 Hz), 145.2 (s), 147.4 (s), 149.7 (s) ppm; IR(cm⁻¹): 3393, 3133, 2959, 1647, 1448, 1300, 1260, 876, 751, 724; HRMS(ESI) calcd for C₁₇ H₁₁O₂N₃CIF₆ (M⁺+H): 438.0439; found: 438.0445.

Example 6

4-chloro-2-(4-(2-hydroxy-2-phenylethyl)-1H-1,2,3-triazol-1-yl)phenol (1ea):

Isolated by column chromatography (pet.ether/AcOEt=6:4, R_(ƒ)=0.4). The title compound was determined as yellow solid (86%). Mp: 177-179° C.; ¹H NMR (200 MHz, CDCl₃+MeOH(D₄)): δ0.73 (t, J=7.3 Hz, 3H), (m, 2 H), 6.82 (d, J =8.8 Hz, 1H), (m, 4H), 7.32-7.43 (m, 2H), 7.55 (d, J=2.5 Hz, 1H), 8.05 (s, 1H) ppm; ¹³C NMR (50 MHz, CDCl₃+MeOH (D₄)): δ 7.3 (q), 34.6 (t), 74.3 (s), 118.1 (d), 122.6 (d), 123.2 (d), 124.2 (s), 124.6 (s), 125.3 (d, 2C), 126.6 (d), 127.7 (d, 2C), 129.1 (d), 144.8 (s), 147.4 (s), 154.1 (s) ppm; IR(cm⁻¹): 3359, 3121, 2960, 1647, 1547, 1428, 1373, 1251, 1163, 966, 855, 754, 673; HRMS(ESI) calcd for C₁₇H₁₇O₂N₃Cl(M⁺+H): 330.1004; found: 330.1007.

Example 7

5-Chloro-2-(4-((3,5-dimethylphenyl)(hydroxy)methyl)-1H-1,2,3-triazol-1-yl)phenol (1ab):

Isolated by column chromatography (pet.ether/AcOEt=6:4, R_(ƒ)=0.3). The title compound was determined as colourless solid (82%). Mp: 223-224° C.; ¹H NMR (200 MHz, CDCl₃): δ 2.31 (s, 6 H), 6.03 (s, 1H), 6.94 (d, J= 2.2, 8.7 Hz, 2H), 7.08 (s, 2H), 7.17 (d, J=2.3 Hz, 1H), 7.28 (d, J=8.6 Hz, 1H), 7.88 (s, 1H); ¹³C NMR (50 MHz, CDCl₃): δ 21.3 (q, 2C), 69.4 (d), 119.1 (d), 119.6 (d), 120.2 (d), 120.4 (d), 121.4 (s), 124.1 (d, 2C), 130.1 (d), 135.0 (s), 138.5 (s, 2C), 141.2 (s), 150.0 (s), 151.6 (s) ppm; IR (cm⁻¹): 3325, 3122, 2987, 2405, 1648, 1567, 1460, 1336, 1226, 1058, 874, 760, 664; HRMS(ESI) calcd for C₁₇H₁₇O₂N₃Cl(M⁺+H): 330.1004; found: 330.1005.

Example 8

5-Chloro-2-(4-(1-hydroxy-1-phenylethyl)-1H-1,2,3-triazol-1-yl)phenol (2cb):

Isolated by column chromatography (pet.ether/AcOEt=6:4, R_(ƒ)=0.4). The title compound was determined as colourless solid (79%). Mp:232-234° C.; ¹H NMR (200 MHz, CDCl₃+MeOH (D₄)): δ 2.02 (s, 3H), 6.96 (dd, J=2.2, 8.6 Hz, 1H ), 7.07 (d, J =2.3 Hz, 1H), 7.22-7.36 (m, 3H), 7.50-7.56 (m, 2H), 7.63 (d J=8.6 1Hz, 1H), 8.20 (s, 1H) ppm; ¹³C NMR (50 MHz, CDCl₃+MeOH (D₄)): δ 28.9 (q), 70.9 (s), 116.2 (d), 119.1 (d), 122.4 (d), 122.8 (s), 124.5 (d, 2C), 124.7 (d), 126.1 (d), 127.2 (d, 2C), 134.3 (s), 146.1 (s), 149.4 (s), 154.3 (s) ppm; IR(cm⁻¹): 3309, 3160, 2987, 1642, 1555, 1443, 1362, 1266, 1109, 1013, 975, 871, 753, 678; HRMS(ESI) calcd for C₁₆H₁₅O₂N₃Cl(M⁺+H): 316.0847; found: 316.0846.

Example 9

4-Chloro-2-(4-(2-hydroxy-2-phenylethyl)-1H-1,2,3-triazol-1-yl)phenol (1ea):

Isolated by column chromatography (pet.ether/AcOEt=6:4, R_(ƒ)=0.3). The title compound was determined as colourless solid (83%). Mp: 148-150° C.; ¹H NMR (200 MHz, CDCl₃+MeOH(D₄)): δ 3.22 (d, J=5.3 Hz, 2H), 5.04 (t, J=6.6 Hz, 1H), 7.03 (d, J=8.8 Hz, 1H), 7.22-7.43 (m, 6H), 7.71 (d, .7-2.5 Hz, 1H), 8.08 (s, 111) ppm; ¹³C NMR (50 MHz, CDCl₃+MeOH (D₄)) δ 34.8 (t), 72.5 (d), 117.7 (d), 123.3 (d), 123.8 (s), 123.9 (d), 124.6 (s), 125.3 (d, 2C), 126.9 (d), 127.8 (d, 2C), 129.0 (d), 143.2 (s), 143.7 (s), 147.4 (s) ppm; IR (cm⁻¹): 3363, 3131, 2998, 1643, 1552, 1314, 1253, 1044, 863, 764, 661; HRMS(ESI) calcd for C₁₆H₁₅O₂N₃Cl (M⁺+H): 316.0847; found: 316.0847.

Example 10

5-Chloro-2-(4-(2-hydroxy-2-phenylethyl)-1H-1,2,3-triazol-1-yl)phenol (1eb):

Isolated by column chromatography (pet.ether/AcOEt=6:4, R_(ƒ)=0.3). The title compound was determined as colourless solid (83%). Mp: 171-172° C.; ¹H NMR (200 MHz, CDCl₃+MeOH (D₄)) δ 3.19 (s, 2H), 5.01 (s, 1H), 6.95 (d, J=8.3 Hz, 1H), 7.06 (s, 1H), 7.25-7.36 (m, 5H), 7.58 (d, J=8.0 Hz, 1H), 8.01 (s, 1H) ppm; ¹³C NMR (50 MHz, CDCl₃+MeOH (D₄)) δ 34.7 (t), 72.4 (d), 116.4 (d), 119.3 (d), 122.9 (s), 124.7 (d), 125.2 (d, 2C), 126.8 (d), 127.6 (d, 3C), 134.4 (s, 2C), 143.2 (s), 149.5 (s) ppm; IR (cm⁻¹): 3341, 3142, 2972, 1651, 1563, 1324, 1221, 1063, 873, 750, 668; HRMS(ESI) calcd for C₁₆H₁₅O₂N₃Cl (M⁺+H): 316.0847; found: 316.0854.

Example 11

4-Chloro-2-(4-(2-hydroxy-2-phenylpropyl)-1H-1,2,3-triazol-1-yl)phenol (2fa):

Isolated by column chromatography (pet.ether/AcOEt=6:4, R₇₁ =0.4). The title compound was determined as colourless solid (79%). Mp: 180-181° C.; 1H NMR (200 MHz, CDCl₃+MeOH (D₄)) δ 1.61 (s, 3H), 3.28 (s, 2H), 6.98 (d, J=8.8 Hz, 1H), 7.20-7.37 (m, 4H), 7.43-7.49 (m, 2H), 7.65 (d, J=2.5 Hz, 1H), 7.83 (s, 1H) ppm; ¹³C NMR (50 MHz, CDCl₃+MeOH (D₄)) δ 27.9 (q), 39.5 (t), 73.0 (s), 117.6 (d), 123.3 (d), 123.7 (s), 124.3 (d, 3C), 124.5 (s), 126.0 (d), 127.4 (d, 2C), 128.9 (d), 142.9 (s), 146.7 (s), 147.4 (s) ppm; IR(cm⁻¹): 3344, 3067, 2950, 1942, 1736, 1645, 1598, 1437, 1303, 1233, 1 158, 880, 748, 624; HRMS(ESI) calcd for C₁₇H₁₇O₂N₃Cl (M⁺+H): 330.1004; found: 330.0999.

Example 12

5-Chloro-2-(4-(2-hydroxy-2-phenylpropyl)-1H-1,2,3-triazol-1-yl)phenol (2fb):

Isolated by column chromatography (pet.ether/AcOEt=6:4, R₇₁=0.4). The title compound was determined as colourless solid (83%). Mp: 189-190° C.; ¹H NMR (200 MHz, CDCl₃+MeOH (D₄)) δ 1.61 (s, 3H), 3.28 (s, 2H), 6.95 (dd, J=2.3, 8.6 Hz, 1H), 7.05 (d, J=2.3 Hz, 1H), 7.22-7.36 (m, 3H), 7.44-7.49 (m, 2H), 7.55 (d, J=8.6 Hz, 1H), 7.76 (s, 1H) ppm; ¹³C NMR (50 MHz, CDCl₃+MeOH (D₄)): δ 28.2 (q). 39.6 (t), 73.1 (s), 116.6 (d), 119.4 (d), 122.9 (s), 124.4 (d, 3C), 124.7 (d), 126.1 (d), 127.5 (d, 2C), 134.5 (s), 142.9 (s), 146.7 (s), 149.6 (s) ppm; IR(cm⁻¹): 3448, 3162, 3022, 2929, 1643, 1552, 1445, 1364, 1263, 1 155, 1006, 923, 874, 763; HRMS(ESI) calcd for C₁₇H₁₇O₂N₃Cl(M⁺+H): 330.1004; found: 330.1009.

Example 13

4-Chloro-2-(4-(2-hydroxy-2-phenylbutyl)-1H-1,2,3-triazol-1-yl)phenol (2ga):

Isolated by column chromatography (pet.ether/AcOEt=6:4, R^(ƒ)=0.4). The title compound was determined as colourless solid (85%). Mp: 153-155° C.; ¹H NMR (400 MHz, CDCl₃+MeOH (D₄)): δ 0.80 (t, J=7.0 Hz, 3H), 1.85-2.02 (s, 1H), 3.32 (s, 2H), 6.97 (d, J=8.0 Hz, 1H), 7.18-7.22 (m, 2H), 7.31 (t, J=7.3 Hz, 2H), 7.37-7.42 (m, 2H), 7.57 (s, 1H), 7.71 (s, 1H) ppm; ¹³C NMR (50 MHz, CDCl₃+MeOH (D₄)): δ 7.5 (q), 34.7 (t), 38.4 (t), 76.5 (s), 118.7 (d), 122.8 (d), 123.4 (d), 124.4 (s, 2C), 125.3 (d, 2C), 126.4 (d), 127.9 (d, 2C), 129.4 (d), 143.5 (s), 144.7 (s), 147.7 (s) ppm; IR(cm⁻¹): 3329, 3 173, 2953, 1632, 1558, 1 558, 1431 , 1373, 1264, 1 161, 971 , 872, 748, 720, 683; HRMS(ESI) calcd for C₁₈H₁₉O₂N₃Cl(M⁺+H): 344.1160; found: 344.1 164.

Example 14

5-Chloro-2-(4-(2-hydroxy-2-phenylbutyl)-1H-1,2,3-triazol-1-yl)phenol (2gb):

Isolated by column chromatography (pet.ether/AcOEt=6:4, R_(ƒ)=0.4). The title compound was determined as yellow solid (80%). Mp: 129-131° C.; ¹H NMR (400 MHz, CDCl₃+MeOH (D₄)): δ 0.79 (t, J=7.4 Hz, 3H), 1.83-2.05 (m, 2H), 3.32 (s, 2H), 6.88 (dd, J=8.5, 2.3 Hz, 1H), 7.05 (d, J=2.3 Hz, 1H), 7.18-7.22 (m, 1H), 7.28-7.34 (m, 3H), 7.38-7.40 (m, 2H), 7.57 (bs, 1H) ppm; ¹³C NMR (50 MHz, CDCl₃+MeOH (D₄)): δ 7.8 (q), 35. 1 (t), 38.5 (t), 76.7 (s), 118.6 (d), 120.2 (d), 122.0 (d), 125.4 (d, 3C), 126.6 (d), 128. 1 (d, 2C), 134.8 (s, 2C), 144.7 (s, 2C), 149.8 (s) ppm; IR(cm⁻¹): 3333, 3329, 2972, 1642, 1547, 1428, 1363, 1271, 1167, 971, 872, 747, 684; HRMS(ESI) calcd for C₁₈H₁₉O₂N₃Cl(M⁺+H): 344.1161; found: 344.1 164.

Example 15

4-chloro-2-(4-(2-hydroxy-2-phenylhexyl)-1H-1,2,3-triazol-1-yl)phenol (2ha):

Isolated by column chromatography (pet.ether/AcOEt=6:4, R_(ƒ)=0.5). The title compound was determined as colourless solid (86%). Mp: 165-167° C.; ¹H NMR (400 MHz, CDCl₃+MeOH (D₄)): δ 0.83 (t, J=7.3 Hz, 3H), 1.01-1.11 (m, 1H), 1.20-1.36 (m, 3H), 1.81-1.89 (m, 1H), 1.91-1.99 (m, 1H), 3.32 (t, J=15.3 Hz, 1H), 4.03 (bs, 2H), 6.98 (d, J=8.8 Hz, 1H), 7.19-7.23 (m, 2H), 7.32 (t, J=7.8 Hz, 1H), 7.40 (d, J=7.5 Hz, 2H), 7.58 (d, J=2.3 Hz, 1H), 7.69 (s) ppm: ¹³C NMR (100 MHz, CDl₃+MeOH (D₄)): δ 13.4 (q), 22.6 (t), 25.2 (t), 38.7 (t), 41 .7 (t), 76.0 (s), 118.2 (d), 123.2 (d), 123.9 (d), 124.1 (s), 124.6 (s), 125.1 (d, 2C), 126. 1 (d), 127.7 (d, 2C), 129.2 (d), 143.2 (s), 145.0 (s), 147.6 (s) ppm; IR(cm⁻¹): 3459, 3116, 2980, 1639, 1547, 1334, 1231, 1056, 869, 750; HRMS(ESI) calcd for C₂₀H₂₃O₂N₃Cl (M⁺+H): 372.1473; found: 372.1471.

Example 16

4-Chloro-2-(4-(2-hydroxy-2,2-diphenylethyl)-1H-1,2,3-triazol-1-yl)phenol (2ia):

Isolated by column chromatography (pet.ether/AcOEt=7:3, R_(ƒ)=0.5). The title compound was determined as colourless solid (83%). Mp: 194-196° C.; ¹H NMR (200 MHz, CDCl₃+MeOH (D₄)): δ 3.82 (s, 2H), 6.96 (d, J=8.7 Hz, 1H), 7.17-7.35 (m, 7H), 7.46-7.51 (m, 6H), 7.58 (d, J=2.5 Hz, 1H, ppm; ¹³C NMR (50 MHz, CDCl₃+MeOH (D₄)): δ 37.9 (t), 77.2 (s), 118.0 (d), 123.3 (d), 124.0 (s), 124.2 (d), 124.5 (s), 125.8 (d. 4C), 126.5 (d, 2C), 127.6 (d, 4C), 129.1 (d), 143.1 (s), 146.0 (s, 2C), 147.5 (s) ppm; IR(cm⁻¹): 3355, 3173, 2988, 1637 1529. 1435, 1263. 1152, 984, 873, 759, 620; HRMS(ESI) calcd for C₂₂H₁₉O₂N₃Cl (M⁺+H): 392.1160: found: 392.1162.

Example 17

5-Chloro-2-(-4-(2-hydroxy-2,2-diphenylethyl)-1H-1,2,3-triazol-1-yl)phenol (2ib):

Isolated by column chromatography (pet.ether/AcOEt=7.3, R₇₁=0.5). The title compound was determined as colourless solid (81%). Mp: 210-212° C.; ¹H NMR (200 MHz, CDCl₃+MeOH (D₄)): δ 3.81 (s, 2H), 6.89 (dd, J=2.2, 8.6 Hz, 1H), 7.02 (m, 1H), 7.15-7.33 (m. 6H), 7.38 (d, J=1.6H), 7.43-7.50 (m, 4H). 7.54 (s, 1H) ppm; ¹³C NMR (50 MHz, CDCl₃+MeOH (D₄)): δ 38.0 (t), 77.2 (s), 117.3 (d), 119.8 (d), 122.8 (s), 123.9 (d), 124.2 (d), 125.9 (d, 4C), 126.7 (d, 2C), 127.8 (d, 4C), 134.7 (s), 143,2 (S) 146.0 (s. 2C). 149.7 (s) ppm: IR-(cm⁻¹): 3321, 3137, 2970, 1639. 1598, 1543, 1437, 1323, 1236, 1152, 870 740, 625; HRMS(ESI) calcd for C₂₂H₁₉O₂N₃Cl (M⁺+H): 392.1160; found: 392.1158.

Example 18

2-(-4-(2-(3,5-Bis(trifluoromethyl)phenyl)-2-hydroxyethyl)-1,2,3-triazol-1-yl)-4-chlorophenol (1ja):

Isolated by column chromatography (pet.ether/AcOEt=6:4, R₇₁ =0.3). The title compound was determined as colourless solid (87%). Mp: 181-183° C.; ¹H NMR (200 MHz, CDCl₃+MeOH (D₄)): δ 3.22 (d, J=6.4 Hz, 2H), 5.19 (t, J=6.4 Hz, 1H), 7.02 (d, J=8.8 Hz, 1H), 7.26 (dd, J=2.7, 8.6 Hz, 1H), 7.76 (d, J=2.7 Hz, 1H), 7.79 (bs, 2H), 7.90 (bs, 2H), 8.17 (s, 1H) ppm; ¹³C NMR (50 MHz, CDCl₃+MeOH (D₄)): δ 34.8 (t), 72.1 (d), 117.7 (d), 120.5 (s), 120.6 (d, J=4.0 Hz), 123.5 (d, 2C), 123.9 (s, 2C), 124.2 (d), 124.6 (s), 125.7 (d, J=2.9 Hz), 129.1 (d), 130.6 (s, d, J=33.3 Hz ), 131.6 (s, d, J=33.3 Hz), 142.8 (s), 146.7 (s), 147.5 (s) ppm; IR(cm⁻¹): 3316, 3097, 2400, 1645, 1563, 1438, 1321, 1220, 1042, 867, 751, 660; HRMS(ESI) calcd for C₁₈H₁₃O₂N₃CIF₆ (M⁺+H): 452.0595; found: 452.0600.

Example 19

2-(4-(2-(3,5-Bis(trifluoromethyl)phenyl)-2-hydroxyethyl)-1H-1,2,3-triazol-1-yl)-5-chlorophenol (1jb):

Isolated by column chromatography (pet.ether/AcOEt=6:4, R_(ƒ)=0.3). The title compound was determined as colourless solid (82%). Mp: 192-194° C.; ¹H NMR (200 MHz, CDCl₃+MeOH (D₄)): δ 3.21 (d, J=6.4 Hz, 2H), 5.19 (t, J=6.3 Hz, 1H), 6.98 (dd, J=2.2, 8.6 Hz, 1H), 7.08 (d, J=2.2 Hz, 1H), 7.60 (d, J=8.6 Hz, 1H), 7.79 (bs, 2H), 7.88 (bs, 2H), 8.09 (bs, 1H) ppm; ¹³C NMR (50 MHz, CDCl₃+MeOH (D₄)): δ 34.9 (t), 71.2 (d), 116.7 (d), 119.6 (d, 2C), 120.3 (s), 120.6 (d, t, J=3.3 Hz), 122.9 (s), 124.8 (d, 2C), 125.8 (d, J=3.3 Hz), 130.3 (s, d, J=33.3 Hz ), 131.6 (s, d, J=32.9 Hz), 134.7 (s, 2C), 146.7 (s, 2C), 149.7 (s) ppm; IR(cm⁻¹): 3298, 3161, 2984, 1645, 1599, 1443, 1309, 1211, 1095, 871, 757, 682; HRMS(ESI) calcd for C₁₈H₁₃O₂N₃CIF₆ (M⁺+H): 452.0595; found: 452.0599.

Example 20

2-(4-(2-(3,5-Bis(trifluoromethyl)phenyl)-2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)-4-chlorophenol (2sa):

Isolated by column chromatography (pet.ether/AcOEt=6:4, R_(ƒ)=0.4). The title compound was determined as colourless solid (85%). Mp: 1642-166° C.; ¹H NMR (200 MHz, CDCl₃+MeOH (D₄)): δ 1.67 (s, 3H), 3.30 (s, 2H), 7.00 (d, J=8.8 Hz, 1H), 7.24 (dd, J=2.5, 8.8 Hz, 1H), 7.69 (d, J=2.5 Hz, 1H), 7.76 (bs, 1H), 7.97 (s, 2H), 8.08 (s, 1H) ppm; ¹³C NMR (50 MHz, CDCl₃+MeOH (D₄)): δ 28.1 (q), 39.4 (t), 72.7 (s), 117.7 (d), 119.9 (d, J=4.0 Hz), 120.3 (s), 123.4 (d, 2C), 123.9 (s, 2C), 124.5 (d), 125.1 (d, d, J=2.9 Hz), 125.7 (s), 129.1 (d), 130.7 (s, d, J=32.9 Hz), 143.2 (s, 2C), 147.7 (s) 150.3 (s) ppm; IR(cm⁻¹): 3453, 3152, 2993, 1640, 1600, 1555, 1437, 1363, 1248, 1160, 1023, 983, 871, 764; HRMS(ESI) calcd for C₁₉H₁₅O₂N₃CIF₆ (M⁺+H): 466.00752; found: 466.0755.

Example 21

2-(4-(2-(3,5-Bis(trifluoromethyl)phenyl)-2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)-5-chlorophenol (2sb):

Isolated by column chromatography (pet.ether/AcOEt=6:4, R_(ƒ)=0.4). The title compound was determined as colourless solid (80%). Mp: 156-158° C.; ¹H NMR (200 MHz, CDCl₃MeOH (D₄)): δ1.68 (s, 3H), 3.29 (s, 2H), 6.96 (dd, J=2.2, 8.6 Hz, 1H), 7.07 (d, J=2.2, 1H), 7.58 (d, J=8.6 Hz, 1H), 7.76 (bs, 1H), 7.97 (s, 2H), 8.01 (s, 1H) ppm; ¹³C NMR (50 MHz, CDCl₃+MeOH (D₄)): δ 28.1 (q), 39.4 (t), 72.8 (s), 116.6 (d), 119.4 (d), 119.9 (d, J=4.0 Hz), 120.3 (s), 122.9 (s), 124.6 (d), 124.8 (d, 2C), 125.1 (d, d, J=2.9 Hz), 125.7 (s), 130.1 (s, d, J=32.9 Hz), 131.4 (s, d, J=32.9 Hz), 134.6 (s), 142.2 (s), 149.6 (s), 150.2 (s) ppm; IR(cm⁻¹): 3322, 3129, 2983, 1633, 1600, 1535, 1427, 1363, 1248, 1170, 1027, 989, 878, 754; HRMS(ESI) calcd for C₁₉H₁₅O₂N₃CIF₆ (M⁺+H): 466.00752; found: 466.0750.

Example 22

4-Chloro-2-(4-(2-(2,4-difluorophenyl)-2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)phenol (2ka)

Brown color solid; 82%; (_(ƒ)=0.3, 30% ethyl acetate/pet.ether); ¹H NMR (200 MHz, {MeOD+CDCl₃}): δ 1.60 (d, J=1.0 Hz, 3H), 3.26 (d, J=14.9 Hz, 1H), 3.44 (d, J=14.8 Hz, 1H), 6.64-6.78 (m, 2H), 6.93 (d, J=8.8 Hz, 1H), 7.15 (dd, J=8.8, 2.5 Hz, 1H), 7.40-7.54 (m, 2H), 7.76 (s, 1H); ¹³C NMR (125 MHz, {MeOD+CDCl₃}): δ 27.4 (q), 37.4 (t), 72.1 (s), 103.5 (dd, J=25.7, 27.7 Hz), 110.1 (dd, J=2.9, 20.0 Hz), 117.8 (d), 123.2 (d), 124.0 (s), 124.1 (d), 124.6 (s), 128.2 (dd, J=6.5, 9.5 Hz), 129.0 (d), 129.3 (s), 143.0 (s), 147.4 (s), 157.8 (s), 159.8 (s), 160.7 (s), 162.6 (s) ppm; HRMS (ESI+): calcd. For C₁₇H₁₄CIF₂N₃O₂ [M+H]⁺ 365.0743; found 366.0816.

Example 23

4-Chloro-2-(4-(2-(2,4-dichlorophenyl)-2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)phenol (2 ma):

Orange color solid; 81%; (R_(ƒ)=0.3, 30% ethyl acetate/pet. ether); ¹H NMR (500 MHz, {MeOD+CDCl₃}): δ 1.92 (s, 3H), 3.64 (d, J=14.9 Hz, 1H, 3.87 (d, J=14.9 Hz, 1H), 7.10 (dd, J=8.9, 2.1 Hz, 1H), 7.20 (d, J=2.1 Hz, 1H), 7.35 (dd, j=8.5, 2.1 Hz, 1H), 7.53 (d, J=2.1 Hz, 1H), 7.71 (d, J=8.5 Hz, 1H), 7.86 (d, J=8.5 Hz, 1H), 8.09 (br. s., 1H); ¹³C NMR (125 MHz, {MeOD+CDCl₃}): δ 26.1 (q), 35.7 (t), 73.4 (s), 116.5 (d), 119.3 (d), 122.9 (s), 124.6 (d), 126.2 (d), 128.9 (d), 129.9 (d), 130.7 (s), 132.6 (s), 134.4 (s), 142.0 (s), 149.5 (s) ppm; HRMS (ESI+): calcd. For C₁₇H₁₄Cl₃N₃O₂ [M+H]⁺ 397.0152; found 398.0224.

Example 24

4-Chloro-2-(4-(2-(4-(dimethylamino)phenyl)-2-hydroxyethyl)-1H-1,2,3-triazol-1-yl)phenol (2pa):

Brown color solid; 84%; (R_(ƒ)=0.3, 35% ethyl acetate/pet.ether); ¹H NMR (200 MHz, {MeOD+CDCl₃}): δ 3.28 (s, 6H), 3.51-3.59 (m, 2H), 5.22-5.34 (m, 1H), 7.11 (d, J=8.8 Hz, 2H), 7.35 (d, J=8.7 Hz, 1H), 7.56 (d, J=2.5 Hz, 1H), 7.58-7.61 (m, 1H), 7.62 (d, J=3.4 Hz, 1H), 8.02 (d, J=2.4 Hz, 1H), 8.37 (s, 1H); ¹³C NMR (125 MHz, {MeOD+CDCl₃}): 535.0 (t), 40.6 (q, 2C), 72.6 (s), 112.7 (d, 2C), 118.8 (d), 122.6 (d), 123.0 (s), 124.5 (s), 126.7 (d, 2C), 127.5 (d), 129.3 (d), 147.7 (s), 150.1 (s) ppm; HRMS (ESI+): calcd. For C₁₈H₁₉CIN₄O₂[M-H₂O]⁺ 358.1197; found 341.1159.

Example 25

5-Chloro-2-(4-(2-(2,4-difluorophenyl)-2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)phenol (2kb):

Brown color solid; 81%; (R_(ƒ)=0.3, 30% ethyl acetate/pet.ether); ¹H NMR (500 MHz, {MeOD+CDCl₃}): δ 1.59 (s, 3H), 3.26 (d, J=14.9 Hz, 1H), 3.41 (d, J=14.9 Hz, 1H), 6.65-6.74 (m, 2H), 6.85 (dd, J=8.6, 2.1 Hz, 1H), 6.98 (d, J=1.9 Hz, 1H), 7.38 (d, J=8.4 Hz, 1H), 7.42-7.49 (m, 1H), 7.73 (s, 1H) ppm; ¹³C NMR (125 MHz, {MeOD+CDCl₃}): δ 28.2 (q), 37.4 (t), 72.8 (s), 103.7 (s), 103.9 (dd, J=26.1, 27.7 Hz), 110.6 (s), 110.7 (dd, J=3.4, 20.20 Hz), 117.8 (d), 120.1 (d), 122.6 (s), 123.0 (d), 123.6 (d), 128.5 (s), 134.8 (s), 143.6 (s), 149.7 (s), 157.9 (s), 159.8 (s), 160.9 (s), 162.9 (s) ppm; HRMS (ESI+): calcd. For C₁₇H₁₄CIF₂N₃O₂ [M+H]⁺ 365.0743; found 366.0814.

Example 26

5-Chloro-2-(4-(2-(2,4-dichlorophenyl)-2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)phenol (2mb):

Orange color solid; 83%; (R_(ƒ)=0.3, 30% ethyl acetate/pet.ether); ¹H NMR (400 MHz, {MeOD+CDCl₃}): δ 1.68 (s, 3H), 3.34 (d, J=15.1 Hz, 1H), 3.78 (d, J=14.7 Hz, 1H), 6.9 (dd, J=8.7, 2.3 Hz, 1H), 6.97 (d, J=2.3 Hz, 1H), 7.09 (dd, J=8.7, 2.3 Hz, 1H), 7.26 (d, J=2.3 Hz, 1H), 7.37 (d, J=8.7 Hz, 1H), 7.61 (d, J=8.7 Hz, 1H), 7.71 (s, 1H); ¹³C NMR (100 MHz, {MeOD+CDCl₃}): δ 27.0 (q), 35.9 (t), 74.3 (s), 117.8 (d), 120.1 (d), 122.7 (s), 123.6 (d), 126.9 (d), 129.4 (d), 130.5 (d), 130.9 (s), 133.2 (s), 134.8 (s), 142.0 (s), 149.7 (s) ppm; HRMS (ESI+): calcd. For C₁₇H₁₄Cl₃N₃O₂ [M+]⁺ 397.0152; found 398.0225.

Example 27

5-Chloro-2-(4-(2-(2-fluoro-4-(trifluoromethyl)phenyl)-2-hydroxyethyl)-1H-1,2,3-triazol-1-yl)phenol (2ob):

Brown color solid; 83%; (R_(ƒ)=0.3, 35% ethyl acetate/pet.ether); ¹ NMR (400 MHz, {MeOD+CDCl₃}): δ 3.0 (d, J=8.3 Hz, 1H), 3.07-3.16 (m, 1H), 4.92 (br. s., 1H), 5.24 (br. s., 1H), 6.76-6.82 (m, 1H), 6.95-7.00 (m, 1H), 7.13 (d, J=9.8 Hz, 1H), 7.28 (br. s., 1H), 7.45 (dd, J=8.7, 2.8 Hz, 1H), 7.55-7.62 (m, 1H), 7.94 (br. s., 1H), 10.06 (br. s., 1H); ¹³C NMR (100 MHz, {MeOD+CDCl}): δ 29.3 (q), 33.9 (t), 66.1 (d), 112.2 (d, J=24.6 Hz), 117.5 (d), 119.7 (d), 120.7 (d), 123.1 (s), 123.3 (s), 124.2 (d), 128.1 (d), 128.2 (s), 134.3 (s), 149.6 (s), 157.4 (s), 159.9 (s) ppm; HRMS (ESI+): calcd. For C₁₇H₁₂CIF₄N₃O₂ [M+H]⁺401.0554; found 402.0621.

Example 28

2-(4-(2-(2,4-Difluorophenyl)-2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)-5-fluorophenol (2kc):

Brown color solid; 81%; (R_(ƒ)=0.3, 35% ethyl acetate/pet.ether); ¹H NMR (200 MHz, {MeOD+CDCl₃}): δ 1.66 (s, 3H), 3.33 (d, J=14.9 Hz, 1H), 3.52 (d, J=14.9 Hz, 1H), 6.64-6.86 (m, 2H), 6.88-7.09 (m, 2H), 7.14-7.36 (m, 1H), 7.40-7.65 (m, 111), 7.85 (s, 1H); ¹³C NMR (50 MHz, {MeOD+CDCl₃}): δ 28.4 (q), 37.4 (t), 72.8 (s), 104.0 (dd, J=25.3, 27.4 Hz), 108.3 (d), 108.8 (d), 110.8 (dd, J=3.3, 20.5 Hz), 116.0 (d), 116.4 (d), 119.1 (d, J=8.42 Hz), 122.2 (d), 128.6 (dd, J=6.2, 9.5 Hz), 129.4 (s), 143.9 (s), 145.0 (s), 153.4 (s), 158.2 (s) ppm; HRMS (ESI+): calcd. For C₁₇H₁₄F₃N₃O₂ [M+H]⁺ 349.1038; found 350.1104.

Example 29

2-(4-(2-(2,4-Dichlorophenyl)-2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)-5-fluorophenol (2mc):

Orange color solid; 86%; (R_(ƒ)=0.3, 30% ethyl acetate/pet.ether); ¹H NMR (200 MHz, {MeOD+CDCl₃}): δ 2.3 (s, 3H), 4.03 (d,J=15.0 Hz, 1H), 4.36 (d, J=15.0 Hz, 1H), 7.50-7.58 (m, 2H), 7.74 (dd, J=8.6, 2.3 Hz, 1H), 7.88-8.00 (m, 2H), 8.26 (d, J=8.6 Hz, 1H), 8.6 (s, 1H); ¹³C NMR (50 MHz, {MeOD+CDCl₃}): δ 26.6 (q), 35.9 (t), 73.9 (s), 109.7 (d), 110.2 (d), 115.6 (d), 116.1 (d), 117.9 (d, J=8.4 Hz, ), 123.7 (d), 126.6 (d), 129.1 (d), 130.3 (d), 130.9 (s), 132.9 (s), 142.0 (s), 143.2 (s), 144.8 (s), 153.1 (s), 157.9 (s) ppm; HRMS (ESI+): calcd. For C₁₇H₁₄F₃N₃O₂ [M+H]⁺ 381.0447; found 382.0515.

Example 30

5-Fluoro-2-(4-(2-(2-fluoro-4-(trifluoromethyl)phenyl)-2-hydroxyethyl)-1H-1,2,3-triazol-1-yl)phenol (2oc):

Brown color solid; 79%; (R_(ƒ)=0.3, 35% ethyl acetate/pet.ether); ¹H NMR (500 MHz, {MeOD+CDCl₃}): δ 3.12 (dd, J=8.2, 14.9 Hz, 1H), 3.15 (dd, J=4.3, 14.9 Hz, 1H), 5.26 (dd, J=4.3, 7.9 Hz, 1H), 6.96 (d, J=2.6 Hz, 1H), 6.90 (d, J=2.0 Hz, 1H), 7.26 (d, J=10.1 Hz, 1H), 7.32 (br. s., 2H), 7.39-7.41 (m, 2H), 7.64 (t, J=7.6 Hz, 1H), 8.09 (s, 1H); ¹³C NMR (125 MHz, {MeOD+CDCl₃}): δ 33.4 (t), 65.0 (d), 109.9 (d), 110.2 (d), 112.5 (d), 116.0 (d), 116.2 (d), 118.1 (d, J=9.1 Hz), 121.0 (t, J=3.6 Hz), 123.5 (d), 128.1 (d, J=4.5 Hz, 1C), 135.0 (s), 143.5 (s), 144.9 (s), 154.7 (s), 156.6 (s), 157.9 (s), 159.9 (s) ppm; HRMS (ESI+): calcd. For C₁₇H₁₄F₃N₃O₂ [M+H]⁺ 385.0850; found 386.0917.

Example 31

5-Fluoro-2-(4-(2-(4-fluorophenyl)-2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)phenol (2qc):

Brown color solid; 83%; (R_(ƒ)=0.3, 30% ethyl acetate/pet.ether); ¹H NMR (500 MHz, {MeOD+CDCl₃}): δ 1.54 (s, 3H), 3.21 (s, 2H), 6.87-7.00 (m, 4H), 7.29 (s, 1H), 7.32-7.42 (m, 2H), 7.76 (s, 1H); ¹³C NMR (125 MHz, {MeOD+CDCl₃}): δ 29.3 (q), 39.9 (t), 73.4 (s), 109.7 (dd, J=27.7 Hz), 114.6 (dd, J=21.0 Hz, 2C), 116.1 (dd, J=22.9 Hz), 118.3 (dd, J=8.6 Hz), 123.5 (d), 126.5 (dd, J=8.6 Hz, 2C), 142.8 (s), 144.9 (s), 154.7 (s), 156.6 (s), 160.5 (s), 162.5 (s) ppm; HRMS (ESI+): calcd. For C₁₇H₁₅F₃N₃O₂ [M+H]⁺ 331.1132; found 332.1199.

Example 32

2-(4-(2-(4-Chlorophenyl)-2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)-5-fluorophenol (21c):

Light orange color solid; 82%; (R_(ƒ)=0.3, 30% ethyl acetate/pet.ether); ¹H NMR (200 MHz, {MeOD+CDCl₃}): δ 1.53 (s, 3H), 3.20 (s, 2H), 6.94 (d, J=5.8 Hz, 2H), 7.30 (s, 2H), 7.25 (s, 1H), 7.31-7.38 (m, 2H), 7.80 (s, 1H); ¹³C NMR (125 MHz, {MeOD+CDCl₃}): δ 29.6 (q), 39.7 (t), 73.5 (s), 109.2 (m, 1C), 116.1 (d, J=22.7 Hz), 118.7 (d, J=8.2 Hz), 122.9 (d), 123.6 (s), 126.3 (d, 2C), 128.1 (d, 2C), 132.4 (s), 143.6 (s), 145.0 (s), 145.7 (s), 154.8 (s) ppm; HRMS (ESI+): calcd. For C₁₇H₁₅CIFN₃O₂ [M+H]⁺ 347.0837; found 348.0903.

Example 33

2-(4-(2-(4-Bromophenyl)-2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)-5-fluorophenol (2nc):

Brown color solid; 83%; (R_(ƒ)=0.3, 30% ethyl acetate/pet.ether); ¹H NMR (200 MHz, {MeOD+CDCl₃}): δ 1.63 (s, 3H), 3.32 (d, J=1.6 Hz, 2H), 6.97-7.06 (m, 2H), 7.10-7.17 (m, 1H), 7.30-7.38 (m, 2H), 7.41-7.49 (m, 2H), 7.68 (s, 1H), 9.62 (s, 1H); ¹³C NMR (50 MHz, {MeOD+CDCl₃}): δ 29.4 (q), 39.6 (t), 73.5 (s), 109.1 (d), 109.6 (d), 115.9 (d), 116.4 (d), 118.5 (dd, J=8.8 Hz), 120.5 (s), 123.1 (d), 126.7 (d, 2C), 131.1 (d, 2C), 1.43.5 (s), 146.2 (s) ppm; HRMS (ESI+): calcd. For C₁₇H₁₃BrFN₃O₂ [M+H]⁺ 391.0332; found 392.0398.

Example 34

4-Chloro-2-(4-(2(4fluorophenyl)-2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)phenol (2qa):

Brown color solid; 79%; (R_(ƒ)=0.3, 30% ethyl acetate/pet.ether); ¹H NMR (200 MHz, {MeOD+CDCl₃}): δ 1.6 (s, 3H), 3.21 (s, 3H), 6.90-6.99 (m, 3H) 7.17 (dd, J=8.8, 2.5 Hz, 1H), 7.33 7.42 (m, 2H), 7.59 (d, J=2.5 1H), 7.77 (s, 1H); ¹³C NMR (50 MHz, {MeOD+CDCl₃}): δ 29.0 (q), 39.9 (t), 73.3 (s), 114.2 (d), 114.7; (d). 118.3 (d), 123.1 (d), 124.3 (s), 126.4 (d, 2C), 126.5 (d, 2C), 129.3 (d, 2C). 142.7 (s). 147.5 (s) ppm; HRMS (ESI+): calcd. For C₁₇H₁₅CIFN₃O₂ [M+H]⁺ 347.0837; found 348.0904.

Example 35

4-Chloro-2-(4-(2-(4-chlorophenyl)-2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)phenol (21a):

Orange color solid; 82%; (R_(ƒ)=0.3, 30% ethyl acetate/pet.ether); ¹H NMR (400 MHz, {MeOD+CDCl₃}): δ 1.54 (s, 3H) 3.21 (s, 2H), 6.94 (m, 3H), 7.59 (d, J=2.5 Hz, 1H), 7.81 (br. s., 1H); ¹³C NMR (101 MHz, {MeOD+CDCl₃}): δ 29.0 (q), 39.6 (t). 73.3 (s), 118.3 (d) 123.2 (d) 123.9 (s), 124.3 (s), 124.6 (s), 126.3 (d, 2C). 127.9 d, 3C), 129.3 (d), 132.2 (s), 145.6 (s), 147.6 (s) ppm; HRMS (ESI⁺): calcd. For C₁₇H₁₅CIFN₃O₂ [M+H]⁺ 363.0541: found 364.0809.

Example 36

2-(4-(2-(4-Bromophenyl)-2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)-4-chlorophenol (2na):

Brown color solid; 83%; (R_(ƒ)=0.3, 30% ethyl acetate/pet.ether); ¹H NMR (200 MHz, {MeOD+CDCl₃}): δ 1.52 (s, 3H), 3.20 (s, 2H), 6.93 (d, J=8.8 Hz, 1H), 7.11-7.42 (m, 5H), 7.52 (d, J=2.5 Hz, 1H), 7.77 (s, 1H); ¹³C NMR (50 MHz, {MeOD+CDCl₃}): δ 29.3 (q), 39.6 (t), 73.5 (s), 118.8 (d), 120.5 (s), 122.7 (d), 123.4 (d), 124.4 (s), 124.5 (s), 126.7 (d, 2C), 129.4 (d), 131.0 (d, 2C), 146.2 (s, 2C), 147.6 (s) ppm; HRMS (ESI⁺): calcd. For C₁₇H₁₅CIFN₃O₂ [M+H]⁺ 407.0036; found 408.0136.

Example 37

5-Chloro-2-(4-(2-(4-fluorophenyl)-2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)phenol (2qb):

Brown color solid; 81%; (R_(ƒ)=0.3, 30% ethyl acetate/pet.ether);¹H NMR (200 MHz, {MeOD+CDCl₃}): δ 1.55 (s, 3H), 3.20 (s, 2H), 6.87 (d, J=2.2 Hz, 1H), 6.90-6.92 (m, 1H), 6.94 (s, 1H), 6.97-7.00 (m, 2H), 7.32-7.40 (m, 2H), 7.46 (d, J=8.6 Hz, 1H), 7.69 (br. s., 1H); ¹³C NMR (50 MHz, {MeOD+CDCl₃}): δ 24.6 (q), 35.3 (t), 68.7 (s), 109.7 (d, J=21.2 Hz, 2C), 112.8 (d), 115.3 (d), 119.6(d, 2C), 121.8 (d, J=8.1 Hz, 2C), 130.2 (s), 138.2 (s), 145.1 (s, 2C), 154.4 (s), 161.9 (s) ppm; HRMS (ESI+): calcd. For C₁₇H₁₅CIFN₃O₂ [M+H]⁺ found 348.0906.

Example 38

5-Chloro-2-(4-(2-(4-chlorophenyl)-2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)phenol (21b):

Orange color solid; 83%; (R_(ƒ)=0.3, 30% ethyl acetate/pet.ether); ¹H NMR (400 MHz, {MeOD+CDCl₃}): δ 51.53 (s, 3H), 3.20 (s, 2H), 6.89 (dd, J=8.7, 2.1 Hz, 1H), 7.00 (d, J=2.2 Hz, 1H), 7.22 (m, J=8.8 Hz, 2H), 7.30-7.36 (m, 2H), 7.45 (d, J=8.6 Hz, 1H), 7.72 (s, 1H); ¹³C NMR (101 MHz, {MeOD+CDCl₃}): δ 29.2 (q), 39.7 (t), 73.4 (s), 117.5 (d), 120.0 (d), 122.9 (s), 124.2 (d), 126.3 (d, 2C), 128.0 (d, 3C), 132.3 (s), 134.8 (s), 145.7 (s, 2C), 149.7 (s) ppm; HRMS (ESI+): calcd. For C₁₇H₁₅Cl₂N₃O₂ [M+H]⁺ 363.0541 ; found 364.0610.

Example 39

2-(4-(2-(4-Bromophenyl)-2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)-5-chlorophenol (2nb):

Brown color solid; 81%; (R_(ƒ)=0.3, 30% ethyl acetate/pet.ether); ¹H NMR (200 MHz, {MeOD+CDCl₃}): δ 1.53 (s, 3H), 3.20 (s, 2H), 6.89 (dd, J=8.6, 2.2 Hz, 1H), 7.00 (d, J=2.2 Hz, 1H), 7.26-7.33 (m, 2H), 7.36 (s, 1H), 7.40 (m, 1H), 7.47 (d, J=8.6 Hz, 1H), 7.74 (s, 1H); ¹³C NMR (50 MHz, {MeOD+CDCl₃}): δ 29.3 (q), 39.6 (t), 73.5 (s), 117.7(d), 120.1 (d), 120.5 (s), 123.9(d), 126.7 (d, 2C), 131.0 (d, 2C), 134.9 (s), 146.2 (s, 2C), 149.7 (s, 2C), 154.7 (s) ppm; HRMS (ESI+): calcd. For C₁₇H₁₅Cl₂N₃O₂ [M+H]⁺ 407.0036; found 408.0136.

Example 40

2-(4-(2-(4-Fluorophenyl)-2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)phenol (2qd):

Brown color solid; 78%; (R_(ƒ)=0.3, 30% ethyl acetate/pct.ether); ¹H NMR (200 MHz, {MeOD+CDCl₃}): δ 1.55 (s, 3H), 3.21 (s, 2H), 6.84-7.05 (m, 4H), 7.14-7.28 (m, 1H), 7.30-7.48 (m, 3H), 7.66 (s, 1H); ¹³C NMR (50 MHz, {MeOD+CDCl₃}): δ 29.4 (q), 39.9 (t), 73.4 (s), 114.6 (d, J=21.2Hz, 2C), 117.8 (d), 119.9 (d), 122.6 (d), 123.1 (d), 123.7 (s), 126.4 (d, J=7.7 Hz, 2C), 129.7 (d), 142.8 (s), 149.0 (s, 2C), 159.1 (s), 163.9 (s) ppm; HRMS (ESI+): calcd. For C₁₇H₁₅Cl₂N₃O₂[M+H]⁺ 313.1227; found 314.1294.

Example 41

2-(4-(2-(4-Chlorophenyl)-2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)phenol (21d):

Orange color solid; 84%; (R_(ƒ)=0.3, 30% ethyl acctatc/pct.ether); ¹H NMR (500 MHz, {MeOD+CDCl₃}): δ 1.56 (br. s., 3H), 3.22 (br. s., 2H), 6.89 6.97 (m, 1H), 7.00 (d, J =7.6 Hz, 1H), 7.20-7.31 (m, 3H), 7.38 (d, J=7.3 Hz, 2H), 7.54 (d, J=7.0 Hz, 1H), 7.83 (br. s., 1H); ¹³C NMR (125 MHz, {MeOD+CDCl₃}): δ 528.4 (q), 39.6 (t), 72.9 (s), 116.7(d), 119.4 (d), 123.6 (d), 123.9 (s), 124.2 (d), 126.1 (d, 2C), 127.6 (d, 2C), 129.5 (d), 131.9 (s), 142.7 (s), 145.6 (s, 2C), 148.9 (s) ppm; HRMS (ESI+): calcd. For C₁₇H₁₅Cl₂N₃O₂[M+H]⁺ 329.0931; found 330.0998.

Example 42

2-(4-(2-(4-Bromophenyl)-2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)phenol (2nd):

Brown color solid; 84%; (R_(ƒ)=0.3, 30% ethyl acetate/pet.ether); ¹H NMR (200 MHz, {MeOD+CDCl₃}): δ 1.53 (s, 3H), 3.21 (s, 2H), 6.86-6.96 (m, 1H), 6.97-7.04 (m, 1H), 7.16-7.24 (m, 1H), 7.27-7.33 (m, 2H), 7.34-7.46 (m, 3H), 7.71 (s, 1H); ¹³C NMR (50 MHz, {MeOD+CDCl₃}): δ 29.3 (q), 39.6 (t), 73.4 (s), 117.8 (d), 120.0 (d), 120.4 (s), 122.6 (d), 123.1 (d), 126.7 (d, 2C), 129.7 (d), 131.0 (d, 2C), 146.3 (s, 2C), 149.0 (s, 2C), 160.9 (s) ppm; HRMS (ESI+): calcd. For C₁₇H₁₅Cl₂N₃O₂[M+H]⁺ 373.0426; found 374.0495.

Example 43

2-(4-(2-(2,4-Difluorophenyl)-2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)phenol (2kd):

Brown color solid; 82%; (R_(ƒ)=0.3, 30% ethyl acetate/pet.ether); ¹H NMR (200 MHz, {MeOD+CDCl₃}): δ 1.68 (s, 3H), 3.38 (s, 1H), 3.47 (s, 1H), 6.70-6.87 (m, 2H), 6.92-7.10 (m, 2H), 7.23-7.36 (m, 1H), 7.43-7.62 (m, 2H), 7.82 (s, 1H); ¹³C NMR (50 MHz, {MeOD+CDCl₃}): δ 28.2 (q), 37.4 (t), 72.7 (s), 103.3 (dd, J=25.6, 27.4 Hz)), 110.6 (dd, J=3.3, 23.8 Hz), 117.8 (d), 119.9 (d), 122.5 (d), 122.9 (d), 123.7 (s), 128.4 (dd, J=6.4, 9.1 Hz), 129.7 (d), 149.0 (s, 2C), 156.3 (s), 159.2 (s), 161.4 (s) ppm; HRMS (ESI+): calcd. For C₁₇H₁₅Cl₂N₃O₂[M+H]⁺ 331.1132; found 332.1 199.

Example 44

2-(4-(2-(2,4-Dichlorophenyl)-2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)phenol (2md):

Brown color solid; 81 %; (R_(ƒ)=0.3, 30% ethyl acetate/pet.ether); ¹H NMR (200 MHz, {MeOD+CDCl₃}): δ 1.71 (s, 3H), 3.39 (d, J=15.0 Hz, 1H), 3.77 (d, J=14.9 Hz, 1H), 6.86-7.03 (m, 2H), 7.09-7.25 (m, 2H), 7.28-7.34 (m, 1H), 7.44 (dd, J=8.0, 1.6 Hz, 1H), 7.64 (d, J=8.6 Hz, 1H), 7.78 (s, 1H); ¹³C NMR (50 MHz, {MeOD+CDCl₃}): δ 26.8 (q), 35.9 (t), 74.1 (s), 117.5 (d), 119.8 (d), 122.8 (d), 123.1 (d), 126.8 (d), 129.3 (d), 129.6 (d), 130.4 (d), 130.9 (s), 133.0 (s), 142.1 (s), 148.9 (s, 2C), 151.6 (s) ppm; HRMS (ESI+): calcd. For C₁₇H₁₅Cl₂N₃O₂[M+H]⁺ 363.0541 ; found 364.061 1.

Example 45 A. Antifungal Activity

The synthesized compounds were evaluated for antifungal susceptibility by microbroth dilution method according to the recommendations of the Clinical Laboratory Standards Institute (CLSI 2008). Briefly, appropriate amount of compounds were dissolved in dimethyl sulfoxide to get 100× final strength. The stock was then diluted 1:50 in RPMI/YPG medium and 200 μl from this was added to the first row of a 96-well microtitre plate. The compounds were serially diluted two fold in successive wells to get a range of 1-128 μg/ml. Fungal yeast cells (˜2×10³ cfu/mL), freshly grown in YPG broth in logarithmic phase, were suspended in the medium and inoculated (100 μl) in the wells of the plate. For filamentous fungi, 2×10⁴ spores/mL were added. The microtitre plate was incubated for 48 h, and the absorbance was measured at 600 nm by using microtitre plate reader to assess cell growth. The MIC was defined as the lowest concentration exhibiting >90% inhibition of visible growth compared to the growth of the control. Results are given in Table 1. Based on the results, compounds 2gb, 2ga, 1db, 2fa, 1ab, 2eb, 2ea, 1da, 1db were identified as promising molecules.

B. Effect of the compounds on sterol profile:

Inhibition of lanosterol 14 a-demethylase by azoles results in depletion of ergosterol. The depletion can be quantified by spectrophotometry. Briefly, Overnight grown C. albicans ATCC 24433 (1×10⁶ cfu/ml) cells were inoculated in a series of flasks containing 50 ml of Yeast extract Peptone Glucose (YPG) broth containing 0, 0.5, 1, 2 mg of fluconazole per ml as well as 0.5 MIC and MIC of the lead compounds. The cultures were incubated for 24 h with shaking at 30° C. The stationary-phase cells were harvested by centrifugation at for 5 min and washed once with sterile distilled water. The net wet weight of the cell pellet was determined. Three milliliters of 25% alcoholic potassium hydroxide solution (25 g of OH and 35 ml of sterile distilled water, brought to 100 ml with 100% ethanol), was added to 125 mg of pellet and vortex mixed for 1 min. Cell suspensions were transferred to sterile borosilicate glass screw-cap tubes and were incubated in an 85° C. water bath for 1 h. Following incubation, tubes were allowed to cool to room temperature. Sterols were then extracted by addition of a mixture of 1 ml of sterile distilled water and 3 ml of n-heptane followed by vigorous vortex mixing for 3 min. The heptane layer was transferred to a clean borosilicate glass screw-cap tube. The sterol extract was scanned spectrophotometrically between 220 and 300 nm with a Spectrophotometer. The presence of ergosterol and the late sterol intermediate 24(28)DHF in the extracted sample resulted in a characteristic four-peaked curve. A dose-dependent decrease in the height of the absorbance peaks was evident and corresponded to decreased ergosterol concentration for fluconazole and all the tested compounds. Compounds 2fa and 2gb were most effective. The sterol profile for negative control compounds lab and 2fa was similar to control. Based on the results, compounds 2ca, 1da and 2ga were identified as potent inhibitors of lanosterol 14 α-demethylase enzyme, exerting their antifungal action through ergosterol depletion.

For compounds 2cb, 1da, 2fa, 1ab no ergosterol depletion was observed indicating different mode of action. Apart from lanosterol 14 a-demethylase inhibition, few azoles like miconazole are known to exert their antifungal action by reactive oxygen species (ROS) generation. Therefore ROS production in C. albicans ATCC 24433 was evaluated for these compounds by using dichlorofluorescin diacetate dye. Compounds 2fa, 2eb, 1da, 1ab showed dose dependent increase in ROS generation in C. albicans ATCC 24433. ROS can damage a wide range of molecules, including nucleic acids, proteins and lipids, can cause apoptosis, necrotic death and with this wide range of targets it is difficult to determine which events lead to loss of viability of cells following damage.

TABLE 1 Organism Candida Candida Cryptococcus Aspergillus Aspergillus albicans albicans Candida neoformans fumigatus niger ATCC ATCC glabrata ATCC MCC ATCC Compound 24433 10231 NCYC 388 34664 1046 10578 2gb 16 16 8 8 8 >128 2ga 16 16 8 16 32 >128 1db 16 32 8 16 >128 >128 2eb 64 32 32 32 32 128 2fa 16 16 8 16 8 >128 2aa >128 ND 128 128 >128 >128 2db >128 128 64 128 128 128 2ab >128 ND 128 >128 128 >128 1ab 32 32 32 32 32 >128 2ia 128 ND 128 >128 128 >128 1ea 64 ND 128 >128 128 64 2hb 64 >128 64 32 >128 >128 2da 128 ND 128 >128 128 64 1aa 64 ND 32 32 64 64 2ea 32 32 64 32 128 64 1ba 128 ND 128 16 >128 >128 1da 16 16 8 16 >128 >128 Fluconazole 2 8 >128 32 >128 >128

TABLE 2 Antifungal activity of the triazole compounds against fungal human pathogens. MIC values (μg/ml) C. albicans C. neoformans C. glabrata A. niger A. fumigatus C. albicans ATCC ATCC NCYC C. tropicalis ATCC MCC Compounds ATCC 24433 10231 34664 388 ATCC 750 10578 1046 3ac 8 ND 128 ND 128 128 64 3bc 16  8 16 16 32 64 64 3cc 128 ND >256 ND >256 >256 >256 3dc 64 ND 256 ND >256 256 128 3ec 8 ND 128 ND 128 128 64 3fc 8 16 64 64 128 128 64 3da 32 32 64 64 128 128 64 3ea 16  8 32 16 64 64 64 3fa 4 ND 32 ND 64 32 16 3db 16 ND 128 ND 128 64 32 3eb 32 16 32 32 64 64 64 3fb 16 16 32 32 64 64 64 3dd 64 ND 256 ND >256 256 256 3ed 8 ND 128 ND 256 128 64 3fd 32 ND 128 ND 256 128 128 3ad 8 ND 128 ND 256 128 128 3bd 8 ND 32 ND 64 32 16 3aa 32 32 64 32 128 128 >256 3ba 32 ND >256 ND >256 >256 >256 3ga 64 16 64 16 >256 >256 >256 3ab 16 32 32 32 64 64 64 3bb 4 16 8 16 32 32 16 3cb 16 ND >256 ND >256 >256 >256 ND—Not done

It will be evident to those skilled in the art that the invention is not limited to the details of the foregoing illustrative examples and that the present invention may be embodied in other specific forms without departing from the essential attributes thereof, and it is therefore desired that the present embodiments and examples be considered in all respects as illustrative and not restrictive, reference being made to the appended claims, rather than to the foregoing description, and all changes which come within the meaning and range of equivalency of the claims arc therefore intended to be embraced therein.

Advantages of Invention

-   -   a. Synthesis of newer azole derivatives.     -   b. The lead molecules identified showed better in vitro         antifungal activity against most of the pathogenic fungi as         compared to fluconazole.     -   c. The compounds inhibited ergosterol biosynthesis, a sterol         absent in humans; hence they will not be toxic or have         side-effects. 

1. Antifungal compounds of the formula (I)

Wherein, R₁ is halogens such as fluorine, chlorine, bromine, CF₃, alkyl; R₂ is alkyl or hydrogen; R₃ is halogen selected from fluorine, chlorine or bromine; and n is 0 or
 1. 2. The compounds of formula (I) according to claim 1, wherein compound of formula (I) are preferably selected from the following: i. 4-Chloro-2-(4-((3,5-dimethylphenyl)(hydroxy)methyl)-1H-1,2,3-triazol-1-yl)phenol (1aa). ii. 2-(4-((3,5-Bis(trifluoromcthyl)phenyl)(hydroxy)methyl)-1H-1,2,3-triazol-1-yl)-4-chlorophenol(1ba), iii. 4-Chloro-2-(4-(1-hydroxy-1-phenylpropyl)-1H-1,2,3-triazol-1-yl)phenol(, iv. 5-Chloro-2-(4-((3,5-dimethylphenyl)(hydroxy)methyl)-1 H-1,2,3-triazol-1-yl)phenol(1ab), v. 5-Chloro-2-(4-(1-hydroxy-1-phenylethyl)-1H-1,2,3-triazol-1-yl)phenol(2cb), vi. 4-Chloro-2-(4-(2-hydroxy-2-phenylethyl)-1H-1,2,3-triazol-1-yl)phenol(1ea), vii. 5-Chloro-2-(4-(2-hydroxy-2-phenylethyl)-1H-1,2,3-triazol-1-yl)phenol(1eb), viii. 4-Chloro-2-(4-(2-hydroxy-2-phenylpropyl)-1H-1,2,3-triazol-1-yl)phenol(2fa), ix. 5-Chloro-2-(4-(2-hydroxy-2-phenylpropyl)-1H-1,2,3-triazol-1-yl)phenol(2fb), x. 4-Chloro-2-(4-(2-hydroxy-2-phenylbutyl)-1H-1,2,3-triazol-1-yl)phenol(2ga), xi. 5-Chloro-2-(4-(2-hydroxy-2-phenylbutyl)-1H-1,2,3-triazol-1-yl)phenol(2gb), xii. 4-chloro-2-(4-(2-hydroxy-2-phenylhexyl)-1H-1,2,3-triazol-1-yl)phenol(2ha), xiii. 4-Chloro-2-(4-(2-hydroxy-2,2-diphenylethyl)-1H-1,2,3-triazol-1-yl)phenol(2ia), xiv. 5-Chloro-2-(4-(2-hydroxy-2,2-diphenylethyl)-1H-1,2,3-triazol-1-yl)phenol(2ib), xv. 2-(4-(2-(3,5-Bis(trinuoromethyl)phenyl)-2-hydroxyethyl)-1H-1,2,3-triazol-1-yl)-4-chlorophenol(1ja), xvi. 2-(4-(2-(3,5-Bis(trifluoromethyl)phenyl)-2-hydroxyethyl)-1H-1,2,3-triazol-1-yl)-5-chlorophenol(1jb), xvii. 2-(4-(2-(3,5-Bis(trifluoromethyl)phenyl)-2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)-4-chlorophenol(2sa), xviii. 2-(4-(2-(3,5-Bis(trifluoromethyl)phenyl)-2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)-5-chlorophenol(2sb), xix. 4-Chloro-2-(4-(2-(2,4-difluorophenyl)-2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)phenol(2ka), xx. 4-Chloro-2-(4-(2-(2,4-dichlorophenyl)-2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)phenol(2ma), xxi. 4-Chloro-2-(4-(2-(4-(dimethylamino)phenyl)-2-hydroxycthyl)-1H-1,2,3-triazol-1-yl)phenol (2pa), xxii. 5-Chloro-2-(4-(2-(2,4-difluorophenyl)-2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)phenol (2kb), xxiii. 5-Chloro-2-(4-(2-(2,4-dichlorophenyl)-2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)phenol (2mb), xxiv. 5-Chloro-2-(4-(2-(2-fluoro-4-(trifluoromethyl)phenyl)-2-hydroxyethyl)-1H-1,2,3-triazol-1-yl)phenol (2ob), xxv. 2-(4-(2-(2,4-Difluorophenyl)-2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)-5-fluorophenol (2kc), xxvi. 2-(4-(2-(2,4-Dichlorophenyl)-2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)-5-fluorophenol (2mc), xxvii. 5-Fluoro-2-(4-(2-(2-fluoro-4-(trifluoromethyl)phenyl)-2-hydroxyethyl)-1H-1,2,3-triazol-1-yl)phenol (2oc), xxviii. 5-Fluoro-2-(4-(2-(4-fluorophenyl)-2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)phenol (2qc), xxix. 2-(4-(2-(4-Chlorophenyl)-2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)-5-fluorophenol (2lc), xxx. 2-(4-(2-(4-Bromophenyl)-2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)-5-fluorophenol (2nc), xxxi. 4-Chloro-2-(4-(2-(4-fluorophenyl)-2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)phenol (2qa), xxxii. 4-Chloro-2-(4-(2-(4-chlorophenyl)-2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)phenol (2la), xxxiii. 2-(4-(2-(4-Bromophenyl)-2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)-4-chlorophenol (2na), xxxiv. 5-Chloro-2-(4-(2-(4-fluorophenyl)-2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)phenol (2qb), xxxv. 5-Chloro-2-(4-(2-(4-chlorophenyl)-2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)phenol (2lb), xxxvi. 2-(4-(2-(4-Bromophenyl)-2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)-5-chlorophenol (2nb), xxxvii. 2-(4-(2-(4-Fluorophenyl)-2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)phenol (2qd), xxxviii. 2-(4-(2-(4-Chlorophenyl)-2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)phenol (2ld), xxxix. 2-(4-(2-(4-Bromophenyl)-2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)phenol (2nd) xl. 2-(4-(2-(2,4-Difluorophenyl)-2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)phenol (2kd) xli. 2-(4-(2-(2,4-Dichlorophenyl)-2-hydroxypropyl)-1H-1,2,3-triazol-1-yl)phenol (2md). Wherein, R is halogens such as fluorine, chlorine or bromine, alky!;
 3. A pharmaceutical composition comprising an antifungal compounds of formula (I) according to claim 1, in combination with at least one pharmaceutical excipient.
 4. A method for treating a fungal infection in a subject, wherein the method comprises administering to the said subject an effective amount of an antifungal compounds of formula (I) according to claim
 1. 5. The method of claim 4, wherein said compounds of formula (I) is administered in combination with at least one pharmaceutical excipient.
 6. A process for the preparation of novel triazole antifungal compounds of formula (I) according to claim 1, wherein the process comprising the steps of: a) Adding sodium ascorbate (0.95 eq) and copper (II) sulfate (0.2 eq) to a solution of 2-azidophenols 5 and alkyne 4 or 7 in ¹BuOH:H₂O (3:1) followed by stirring at room temperature (25°-30° C.) for a period of time ranging between 10 min - 1 hour to obtain brick reddish reaction mixture; b) Diluting and extracting the reaction mixture obtained in step (a) followed by purifying and drying to get the pure product.
 7. The process according to claim 6, wherein 2-azidophenols is selected from the group consisting of


8. The process according to claim 6, wherein alkyne is selected from the group consisting of 